Agnello Luisa, Bivona Giulia, Lo Sasso Bruna, Scazzone Concetta, Bazan Viviana, Bellia Chiara, Ciaccio Marcello
Sezione Biochimica Clinica e Medicina Molecolare Clinica, Dipartimento di Biopatologia e Biotecnologie Mediche, Università degli Studi di Palermo, Italy.
Dipartimento di Discipline Chirurgiche, Oncologiche e Stomatologiche, Università degli Studi di Palermo, Italy.
Clin Biochem. 2017 Sep;50(13-14):797-803. doi: 10.1016/j.clinbiochem.2017.04.018. Epub 2017 Apr 26.
Acute coronary syndrome (ACS) is a very common cause of hospitalizations worldwide each year. In the past decades biomarkers have become an indispensable tool for diagnosis, risk stratification and prognosis of cardiovascular disease, including ACS. Despite Troponin is considered the gold standard in diagnosis of ACS, several molecules have been investigated to identify predictive biomarkers of prognosis. Among these, Gal-3 has emerged as a promising prognostic marker. It has a pivotal role in inflammation and fibrosis. Both experimental and clinical studies have shown Gal-3 is an independent predictor of all-cause mortality, cardiovascular death and occurrence of HF following ACS. This article reviews the literature data regarding the role of Galectin-3 in ACS setting.
急性冠状动脉综合征（ACS）是全球每年住院治疗的常见病因。在过去几十年中，生物标志物已成为心血管疾病（包括ACS）诊断、危险分层和预后评估中不可或缺的工具。尽管肌钙蛋白被认为是ACS诊断的金标准，但人们已对多种分子进行了研究，以确定预后的预测生物标志物。其中，半乳糖凝集素-3（Gal-3）已成为一种很有前景的预后标志物。它在炎症和纤维化过程中起关键作用。实验研究和临床研究均表明，Gal-3是ACS后全因死亡率、心血管死亡及心力衰竭发生的独立预测因子。本文综述了有关半乳糖凝集素-3在ACS环境中作用的文献数据。
